Evotec SE
EVO Nasdaq Pharmaceutical Preparations Financials FY2019–FY2025
Revenue
Total sales reported in the income statement.
$889M
3.1%
vs prior year
Operating margin
Operating income as a share of revenue.
−7.1%
10.8 pts
Net income
Profit after all expenses, interest and tax.
−$117M
Free cash flow
Cash from operations minus capital spending.
−$92.2M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−6.3%
6.2 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$0.33 EPS (TTM)
What Evotec SE does
No business description yet.
- Legal name
- Evotec SE
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 8, 2026
- Accession · CIK
- 0001104659-26-040767
0001412558
Revenue and margins
Evotec SE had $889M of revenue in fiscal 2025, up 3.1% on the year before.
FY19
Revenue $500M
FY20
Revenue $571M
FY21
Revenue $731M
FY22
Revenue $790M
FY23
Revenue $845M
FY24
Revenue $862M
FY25
Revenue $889M
FY19
Gross 29.8%
Operating 14.0%
Net 8.5%
FCF 2.4%
FY20
Gross 25.1%
Operating 9.7%
Net 1.3%
FCF −10.9%
FY21
Gross 24.5%
Operating 6.6%
Net 34.9%
FCF 1.2%
FY22
Gross 23.2%
Operating 2.8%
Net −23.4%
FCF 3.3%
FY23
Gross 22.4%
Operating −6.1%
Net −10.7%
FCF −22.6%
FY24
Gross 14.4%
Operating −17.9%
Net −24.6%
FCF −12.5%
FY25
Gross 14.5%
Operating −7.1%
Net −13.1%
FCF −10.4%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY19
Net income $42.7M
FY20
Net income $7.2M
FY21
Net income $255M
FY22
Net income −$185M
FY23
Net income −$90.7M
FY24
Net income −$212M
FY25
Net income −$117M
FY19
Diluted EPS $0.14
FY20
Diluted EPS $0.02
FY21
Diluted EPS $0.77
FY22
Diluted EPS −$0.52
FY23
Diluted EPS −$0.25
FY24
Diluted EPS −$0.60
FY25
Diluted EPS −$0.33
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY19
Return on capital —
Return on equity 7.9%
Return on assets —
FY20
Return on capital 4.6%
Return on equity 1.0%
Return on assets 0.4%
FY21
Return on capital 3.7%
Return on equity 20.8%
Return on assets 11.8%
FY22
Return on capital 1.5%
Return on equity −13.1%
Return on assets −7.5%
FY23
Return on capital −3.5%
Return on equity −7.2%
Return on assets −3.7%
FY24
Return on capital −12.6%
Return on equity −19.0%
Return on assets −9.5%
FY25
Return on capital −6.3%
Return on equity −12.0%
Return on assets −5.8%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$92.2M in fiscal 2025, −10.4% of revenue. Cash from operations minus capital spending.
FY19
Free cash flow $12.2M
FY20
Free cash flow −$61.9M
FY21
Free cash flow $9.1M
FY22
Free cash flow $25.7M
FY23
Free cash flow −$191M
FY24
Free cash flow −$107M
FY25
Free cash flow −$92.2M
FY19
Cash from operations $47.3M
Capital spending $35.1M
FY20
Cash from operations $51.0M
Capital spending $113M
FY21
Cash from operations $150M
Capital spending $141M
FY22
Cash from operations $216M
Capital spending $191M
FY23
Cash from operations $39.4M
Capital spending $231M
FY24
Cash from operations $19.7M
Capital spending $127M
FY25
Cash from operations −$10.4M
Capital spending $81.8M
Cash from operations
Capital spending
Dividends, buybacks and share count
Evotec SE returned $1.7M to shareholders in fiscal 2025. The diluted share count rose 0.2%.
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks $1.7M
Dividends
Buybacks
FY19
Diluted shares 0.30B
FY20
Diluted shares 0.31B
FY21
Diluted shares 0.33B
FY22
Diluted shares 0.35B
FY23
Diluted shares 0.35B
FY24
Diluted shares 0.35B
FY25
Diluted shares 0.36B
Balance sheet
Cash, debt and the ratios that show how comfortably Evotec SE can carry it.
FY19
Cash $311M
Debt —
FY20
Cash $519M
Debt $406M
FY21
Cash $792M
Debt $411M
FY22
Cash $443M
Debt $352M
FY23
Cash $565M
Debt $483M
FY24
Cash $318M
Debt $299M
FY25
Cash $492M
Debt $325M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $792M | $443M | $565M | $318M | $492M |
| Debt incl. finance leases | $411M | $352M | $483M | $299M | $325M |
| Net debt / EBITDA | −2.9x | −0.8x | −1.7x | — | −3.4x |
| Debt / equity | 0.3x | 0.3x | 0.4x | 0.3x | 0.3x |
| Interest coverage | 4.4x | 1.6x | — | — | — |
| Current ratio | 3.4x | 3.2x | 1.9x | 2.0x | 2.1x |
| Quick ratio | 3.3x | 3.1x | 1.9x | 1.9x | 2.0x |
| Total assets | $2.5B | $2.4B | $2.5B | $2.0B | $2.0B |
| Total liabilities | $971M | $1.1B | $1.3B | $997M | $1.1B |
| Shareholders' equity | $1.6B | $1.3B | $1.2B | $990M | $956M |
| Net debt (− = net cash) | −$382M | −$91.0M | −$81.6M | −$19.6M | −$167M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ |
| Return on assets rose | — | — | ✓ | ✕ | ✓ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | ✓ | ✓ | ✕ | ✓ | ✕ |
| Current ratio rose | — | — | ✓ | ✕ | ✕ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Revenue rose relative to assets | — | — | ✕ | ✓ | ✓ | ✓ | ✓ |
| F-score | — / 3 | — / 5 | 5 / 9 | 4 / 9 | 4 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | — | −2.4% | 4.9% | −16.2% | −5.3% | −10.4% | −5.3% |
| Altman Z'' | — | 2.29 | 3.78 | 2.80 | 1.49 | 0.53 | 0.77 |
7 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $500M | $571M | $731M | $790M | $845M | $862M | $889M |
| Gross profit | $149M | $143M | $179M | $183M | $189M | $124M | $129M |
| Research and development | $65.4M | $72.9M | $85.4M | $80.6M | $74.1M | $55.0M | $42.3M |
| Operating income | $70.2M | $55.3M | $48.5M | $21.9M | −$51.4M | −$154M | −$63.4M |
| Interest expense | $8.3M | $9.6M | $10.9M | $13.8M | — | — | — |
| Pretax income | $63.4M | $29.5M | $280M | −$162M | −$87.2M | −$210M | −$97.8M |
| Income tax | $21.7M | $22.3M | $25.4M | $22.8M | $3.6M | $2.3M | $18.9M |
| Net income | $42.7M | $7.2M | $255M | −$185M | −$90.7M | −$212M | −$117M |
| Net income to common | $42.7M | $7.2M | $255M | −$185M | — | — | — |
| Diluted EPS | $0.14 | $0.02 | $0.77 | −$0.52 | −$0.25 | −$0.60 | −$0.33 |
| Diluted shares | 0.30B | 0.31B | 0.33B | 0.35B | 0.35B | 0.35B | 0.36B |
| Cash flow | |||||||
| Cash from operations | $47.3M | $51.0M | $150M | $216M | $39.4M | $19.7M | −$10.4M |
| Capital expenditure | $35.1M | $113M | $141M | $191M | $231M | $127M | $81.8M |
| Free cash flow | $12.2M | −$61.9M | $9.1M | $25.7M | −$191M | −$107M | −$92.2M |
| Depreciation and amortization | — | — | $83.3M | $87.4M | $101M | $110M | $112M |
| Stock-based compensation | $4.1M | $6.0M | $9.2M | $10.4M | $10.4M | $5.4M | $4.3M |
| Acquisitions | $45.1M | $12.5M | $0.5M | $21.9M | −$2.3M | — | — |
| Share buybacks | — | — | — | — | — | — | $1.7M |
| Dividends and buybacks | — | — | — | — | — | — | $1.7M |
| Balance sheet | |||||||
| Cash and short-term investments | $311M | $519M | $792M | $443M | $565M | $318M | $492M |
| Total debt | — | $406M | $411M | $352M | $483M | $299M | $325M |
| Current assets | — | $808M | $1.2B | $1.1B | $998M | $708M | $896M |
| Current liabilities | — | $256M | $368M | $360M | $513M | $358M | $432M |
| Inventory | — | $16.7M | $29.2M | $31.8M | $34.1M | $32.3M | $34.4M |
| Property and equipment, net | $269M | $414M | $549M | $694M | — | — | — |
| Goodwill | $287M | $304M | $292M | $293M | $305M | $294M | $320M |
| Intangible assets | $131M | $120M | $34.9M | $25.4M | $17.1M | $27.5M | $37.1M |
| Total assets | — | $1.8B | $2.5B | $2.4B | $2.5B | $2.0B | $2.0B |
| Total liabilities | — | $905M | $971M | $1.1B | $1.3B | $997M | $1.1B |
| Shareholders' equity | $538M | $889M | $1.6B | $1.3B | $1.2B | $990M | $956M |
| Margins | |||||||
| Gross margin | 29.8% | 25.1% | 24.5% | 23.2% | 22.4% | 14.4% | 14.5% |
| Operating margin | 14.0% | 9.7% | 6.6% | 2.8% | −6.1% | −17.9% | −7.1% |
| EBITDA margin | — | — | 18.0% | 13.8% | 5.8% | −5.1% | 5.5% |
| Net margin | 8.5% | 1.3% | 34.9% | −23.4% | −10.7% | −24.6% | −13.1% |
| FCF margin | 2.4% | −10.9% | 1.2% | 3.3% | −22.6% | −12.5% | −10.4% |
| Returns | |||||||
| Return on capital | — | 4.6% | 3.7% | 1.5% | −3.5% | −12.6% | −6.3% |
| Return on capital employed | — | 3.6% | 2.2% | 1.1% | −2.6% | −9.5% | −4.0% |
| Return on equity | 7.9% | 1.0% | 20.8% | −13.1% | −7.2% | −19.0% | −12.0% |
| Return on assets | — | 0.4% | 11.8% | −7.5% | −3.7% | −9.5% | −5.8% |
| Return on tangible equity | 36.0% | 1.5% | 20.7% | −19.5% | −9.9% | −31.7% | −19.5% |
| Growth | |||||||
| Revenue growth | — | 14.3% | 28.0% | 8.1% | 7.0% | 2.0% | 3.1% |
| Net income growth | — | −83.2% | 3,461.9% | −172.4% | — | — | — |
| EPS growth | — | −83.7% | 3,271.9% | −167.7% | — | — | — |
| FCF growth | — | −608.0% | — | 183.9% | −844.1% | — | — |
| Share count change | — | 2.7% | 8.2% | 6.2% | 0.1% | 0.2% | 0.2% |
| Financial health | |||||||
| Net debt / EBITDA | — | — | −2.9x | −0.8x | −1.7x | — | −3.4x |
| Debt / equity | — | 0.5x | 0.3x | 0.3x | 0.4x | 0.3x | 0.3x |
| Interest coverage | 8.4x | 5.7x | 4.4x | 1.6x | — | — | — |
| Current ratio | — | 3.2x | 3.4x | 3.2x | 1.9x | 2.0x | 2.1x |
| Quick ratio | — | 3.1x | 3.3x | 3.1x | 1.9x | 1.9x | 2.0x |
| Capital allocation | |||||||
| Capex / revenue | 7.0% | 19.8% | 19.2% | 24.1% | 27.3% | 14.7% | 9.2% |
| Stock comp / revenue | 0.8% | 1.1% | 1.3% | 1.3% | 1.2% | 0.6% | 0.5% |
| Quality scores | |||||||
| Piotroski F-score | — | — | 5.0 | 4.0 | 4.0 | 5.0 | 5.0 |
| Altman Z'' | — | 2.3 | 3.8 | 2.8 | 1.5 | 0.5 | 0.8 |
| Accruals ratio | — | −2.4% | 4.9% | −16.2% | −5.3% | −10.4% | −5.3% |
Source: SEC EDGAR XBRL filings (CIK 0001412558). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 0.50 ordinary shares). For information only — not investment advice. Check the original filings before relying on any figure.